J Korean Neuropsychiatr Assoc.  2019 Aug;58(3):167-172. 10.4306/jknpa.2019.58.3.167.

Neurobiological Basis of Craving and Anti-Craving Medications

• Jung YC

• KMID: 2456596
• DOI: http://doi.org/10.4306/jknpa.2019.58.3.167

Abstract

Clinical studies published over the past two decades have consistently demonstrated the therapeutic efficacy and safety of anti-craving medications. To use anti-craving agents more effectively in clinical settings, it is important to set clear treatment goals. Because alcoholic patients have lost control of drinking alcohol, it is recommended to set "˜abstinence' as a goal rather than "˜controlled drinking'. Indeed, the therapeutic effects of anti-craving medication are higher when abstinence is set as the target. On the other hand, if abstinence is the sole criterion, it is difficult to elicit the motivation of a patient who lacks motivation in clinical practice. In the case of patients who have not yet gained insight, the initial goal might be set to gradually reduce the amount of alcohol consumed and prevent at-risk heavy drinking. Even in this case, anti-craving can help clinically. To increase the effectiveness of anti-craving medications, it is best to start at least four to seven days after the patient has stopped drinking. If the patient has alcohol withdrawal symptoms, they should be treated first.

Keyword

Alcohol use disorder; Craving; Naltrexone; Acamprosate

MeSH Terms

Alcoholics
Craving*
Drinking
Hand
Humans
Motivation
Naltrexone
Substance Withdrawal Syndrome
Therapeutic Uses
Naltrexone
Therapeutic Uses

Reference

1. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992; 49:876–880.

2. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992; 49:881–887.

3. American Psychiatry Association. Diagnostic and statistical manual of mental disorders. DSM-5. 5th edition. Arlington: American Psychaitry Association;2013.

4. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993; 18:247–291.

5. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction. 2001; 96:103–114.

6. Sterling p, Eyer J. Allostasis: a new paradigm to explain arousal pathology. In : Fisher S, Reason J, editors. Handbook of life stress, cognition and health. New York, NY: John Wiley;1988. p. 629–649.

7. McEwen BS. Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharmacology. 2000; 22:108–124.

8. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997; 278:52–58.

9. Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol. 2008; 59:29–53.

10. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013; 108:275–293.

11. Ray LA, Chin PF, Miotto K. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets. 2010; 9:13–22.

12. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004; 28:51–63.

13. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. 2003; 38:135–141.

14. Gueorguieva R, Wu R, O'Connor PG, Weisner C, Fucito LM, Hoffmann S, et al. Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT. Alcohol Clin Exp Res. 2014; 38:2647–2656.

15. rethinkingdrinking.niaaa.nih.gov [homepage on the Internet]. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism;cited 2019 Jun 20. Available from: https://www.rethinkingdrinking.niaaa.nih.gov/How-much-is-too-much/Is-your-drinking-patternrisky/Whats-At-Risk-Or-Heavy-Drinking.aspx.

16. Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014; 311:1889–1900.

17. Jung YC, Namkoong K. Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention. Yonsei Med J. 2006; 47:167–178.

18. Kiefer F, Wiedemann K. Combined therapy: what does acamprosate and naltrexone combination tell us? Alcohol Alcohol. 2004; 39:542–547.

19. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003; 60:92–99.